Laurent Meijer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8861779/publications.pdf

Version: 2024-02-01

304	29,475	8749 75	6294 158
papers	citations	h-index	g-index

313	313	313	30917
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis. Journal of Innate Immunity, 2016, 8, 330-349.	1.8	3,509
2	Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nature Medicine, 2004, 10, 55-63.	15.2	1,920
3	Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases cdc2, cdk2 and cdk5. FEBS Journal, 1997, 243, 527-536.	0.2	1,215
4	Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biology, 1999, 1, 60-67.	4.6	752
5	GSK-3-Selective Inhibitors Derived from Tyrian Purple Indirubins. Chemistry and Biology, 2003, 10, 1255-1266.	6.2	720
6	Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors. , 1998, 281, 533-538.		707
7	Indirubins Inhibit Glycogen Synthase Kinase-3Î² and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease. Journal of Biological Chemistry, 2001, 276, 251-260.	1.6	633
8	Inhibition of Cyclin-Dependent Kinases by Purine Analogues. Crystal Structure of Human cdk2 Complexed with Roscovitine. FEBS Journal, 1997, 243, 518-526.	0.2	590
9	Inhibition of Cyclin-Dependent Kinases by Purine Analogues. FEBS Journal, 1994, 224, 771-786.	0.2	576
10	Pharmacological inhibitors of glycogen synthase kinase 3. Trends in Pharmacological Sciences, 2004, 25, 471-480.	4.0	559
11	cdc2 is a component of the M phase-specific histone H1 kinase: Evidence for identity with MPF. Cell, 1988, 55, 371-378.	13.5	558
12	Pharmacological inhibitors of cyclin-dependent kinases. Trends in Pharmacological Sciences, 2002, 23, 417-425.	4.0	543
13	Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature, 1999, 402, 669-671.	13.7	538
14	Constitutive Phosphorylation of the Parkinson's Disease Associated Î±-Synuclein. Journal of Biological Chemistry, 2000, 275, 390-397.	1.6	450
15	Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases. Journal of Medicinal Chemistry, 2004, 47, 935-946.	2.9	343
16	Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials. Accounts of Chemical Research, 2003, 36, 417-425.	7.6	335
17	Paullones are potent inhibitors of glycogen synthase kinase-3Î² and cyclin-dependent kinase 5/p25. FEBS Journal, 2000, 267, 5983-5994.	0.2	330
18	Paullones, a Series of Cyclin-Dependent Kinase Inhibitors:â€‰Synthesis, Evaluation of CDK1/Cyclin B Inhibition, and in Vitro Antitumor Activity. Journal of Medicinal Chemistry, 1999, 42, 2909-2919.	2.9	314

#	Article	IF	Citations
19	Roscovitine Targets, Protein Kinases and Pyridoxal Kinase. Journal of Biological Chemistry, 2005, 280, 31208-31219.	1.6	312
20	Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiffâ€™s bases. Bioorganic and Medicinal Chemistry, 2006, 14, 3758-3765.	1.4	270
21	Multiple modes of ligand recognition: Crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins: Structure, Function and Bioinformatics, 1995, 22, 378-391.	1.5	258
22	Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chemistry and Biology, 1999, 6, 361-375.	6.2	250
23	Protein Kinase MARK/PAR-1 Is Required for Neurite Outgrowth and Establishment of Neuronal Polarity. Molecular Biology of the Cell, 2002, 13, 4013-4028.	0.9	240
24	Cytokinin-Derived Cyclin-Dependent Kinase Inhibitors:Â Synthesis and cdc2 Inhibitory Activity of Olomoucine and Related Compounds. Journal of Medicinal Chemistry, 1997, 40, 408-412.	2.9	225
25	ATP-site Directed Inhibitors of Cyclin-dependent Kinases. Current Medicinal Chemistry, 1999, 6, 859-875.	1.2	215
26	Chemical inhibitors of cyclin-dependent kinases. Trends in Cell Biology, 1996, 6, 393-397.	3.6	202
27	Meridianins, a new family of protein kinase inhibitors isolated from the Ascidian Aplidium meridianum. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1703-1707.	1.0	187
28	High developmental competence of cattle oocytes maintained at the germinal vesicle stage for 24 hours in culture by specific inhibition of MPF kinase activity. Molecular Reproduction and Development, 2000, 55, 89-95.	1.0	181
29	Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B. Journal of Medicinal Chemistry, 2012, 55, 9312-9330.	2.9	174
30	Mechanism of CDK5/p25 Binding by CDK Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 671-679.	2.9	173
31	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3Î². Bioorganic and Medicinal Chemistry Letters, 2004, 14, 413-416.	1.0	171
32	Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nature Biotechnology, 2003, 21, 1075-1081.	9.4	168
33	Meriolins (3-(Pyrimidin-4-yl)-7-azaindoles): Synthesis, Kinase Inhibitory Activity, Cellular Effects, and Structure of a CDK2/Cyclin A/Meriolin Complex. Journal of Medicinal Chemistry, 2008, 51, 737-751.	2.9	144
34	Maturation and Fertilization in Starfish Oocytes. International Review of Cytology, 1984, 86, 129-196.	6.2	141
35	Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects. Journal of Medicinal Chemistry, 2003, 46, 222-236.	2.9	139
36	Inhibitor Binding to Active and Inactive CDK2. Structure, 2001, 9, 389-397.	1.6	137

#	Article	IF	Citations
37	Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions. FEBS Letters, 1994, 353, 207-211.	1.3	135
38	The Cyclin-Dependent Kinase Inhibitors Olomoucine and Roscovitine Arrest Human Fibroblasts in G1 Phase by Specific Inhibition of CDK2 Kinase Activity. Experimental Cell Research, 1998, 245, 8-18.	1.2	134
39	Anti-mitotic properties of indirubin-3â€²-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene, 2001, 20, 3786-3797.	2.6	132
40	Intracellular Targets of Paullones. Journal of Biological Chemistry, 2002, 277, 25493-25501.	1.6	132
41	Leucettines, a Class of Potent Inhibitors of cdc2-Like Kinases and Dual Specificity, Tyrosine Phosphorylation Regulated Kinases Derived from the Marine Sponge Leucettamine B: Modulation of Alternative Pre-RNA Splicing. Journal of Medicinal Chemistry, 2011, 54, 4172-4186.	2.9	130
42	Inhibition of Human Immunodeficiency Virus Type 1 Transcription by Chemical Cyclin-Dependent Kinase Inhibitors. Journal of Virology, 2001, 75, 7266-7279.	1.5	129
43	Synthesis and Target Identification of Hymenialdisine Analogs. Chemistry and Biology, 2004, 11, 247-259.	6.2	128
44	Anticancer Alkaloid Lamellarins Inhibit Protein Kinases. Marine Drugs, 2008, 6, 514-527.	2.2	128
45	Roscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1. Journal of Medicinal Chemistry, 2008, 51, 5229-5242.	2.9	124
46	Sequential Dephosphorylation of p34 on Thr-14 and Tyr-15 at the Prophase/Metaphase Transition. Journal of Biological Chemistry, 1996, 271, 27847-27854.	1.6	120
47	Cyclic activation of histone H1 kinase during sea urchin egg mitotic divisions. Experimental Cell Research, 1988, 174, 116-129.	1.2	119
48	Crystal Structure of a Human Cyclin-Dependent Kinase 6 Complex with a Flavonol Inhibitor, Fisetin. Journal of Medicinal Chemistry, 2005, 48, 737-743.	2.9	119
49	Pharmacological Cyclin-Dependent Kinase Inhibitors Inhibit Replication of Wild-Type and Drug-Resistant Strains of Herpes Simplex Virus and Human Immunodeficiency Virus Type 1 by Targeting Cellular, Not Viral, Proteins. Journal of Virology, 2002, 76, 7874-7882.	1.5	109
50	Improved Tumor Control through Circadian Clock Induction by Seliciclib, a Cyclin-Dependent Kinase Inhibitor. Cancer Research, 2006, 66, 10720-10728.	0.4	109
51	Chemical inhibitors of cyclin-dependent kinases. Methods in Enzymology, 1997, 283, 113-128.	0.4	108
52	Cyclin-Dependent KinasesInitial Approaches to Exploit a Novel Therapeutic Target. , 1999, 82, 285-292.		108
53	Soluble 3â€²,6-Substituted Indirubins with Enhanced Selectivity toward Glycogen Synthase Kinase -3 Alter Circadian Period. Journal of Medicinal Chemistry, 2008, 51, 6421-6431.	2.9	105
54	Degradation of Hof1 by SCFGrr1 is important for actomyosin contraction during cytokinesis in yeast. EMBO Journal, 2005, 24, 1440-1452.	3.5	104

#	Article	IF	Citations
55	The Effect of the Cyclin-Dependent Kinase Inhibitor Olomoucine on Cell Cycle Kinetics. Experimental Cell Research, 1997, 236, 4-15.	1.2	103
56	Pfnek-1, a NIMA-related kinase from the human malaria parasitePlasmodium falciparum. FEBS Journal, 2001, 268, 2600-2608.	0.2	103
57	Meriolins, a New Class of Cell Deathâ€"Inducing Kinase Inhibitors with Enhanced Selectivity for Cyclin-Dependent Kinases. Cancer Research, 2007, 67, 8325-8334.	0.4	103
58	Synthesis, Protein Kinase Inhibitory Potencies, and in Vitro Antiproliferative Activities of Meridianin Derivatives. Journal of Medicinal Chemistry, 2011, 54, 4474-4489.	2.9	100
59	Roscovitine, a novel cyclin-dependent kinase inhibitor, characterizes restriction point and G2/M transition in tobacco BY-2 cell suspension. Plant Journal, 1997, 12, 191-202.	2.8	98
60	Evaluation and Comparison of 3D-QSAR CoMSIA Models for CDK1, CDK5, and GSK-3 Inhibition by Paullones. Journal of Medicinal Chemistry, 2004, 47, 22-36.	2.9	98
61	Synthesis ofÂ3-substituted-2-oxoindole analogues andÂtheirÂevaluation asÂkinase inhibitors, anticancer andÂantiangiogenic agents. European Journal of Medicinal Chemistry, 2006, 41, 296-305.	2.6	98
62	Structure-Based Design and Synthesis of 2-Benzylidene-benzofuran-3-ones as Flavopiridol Mimics. Journal of Medicinal Chemistry, 2002, 45, 1741-1747.	2.9	96
63	Inhibitors of Leishmania mexicana CRK3 Cyclin-Dependent Kinase: Chemical Library Screen and Antileishmanial Activity. Antimicrobial Agents and Chemotherapy, 2004, 48, 3033-3042.	1.4	96
64	Plasmodium falciparum glycogen synthase kinase-3: molecular model, expression, intracellular localisation and selective inhibitors. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2004, 1697, 181-196.	1.1	95
65	Autophagy: A Novel Mechanism of Synergistic Cytotoxicity between Doxorubicin and Roscovitine in a Sarcoma Model. Cancer Research, 2008, 68, 7966-7974.	0.4	95
66	Synthesis and Biological Evaluation of Novel Phenylcarbazoles as Potential Anticancer Agents. Journal of Medicinal Chemistry, 2006, 49, 789-799.	2.9	94
67	Synthesis of acridinyl-thiazolino derivatives and their evaluation for anti-inflammatory, analgesic and kinase inhibition activities. Bioorganic and Medicinal Chemistry, 2005, 13, 4291-4299.	1.4	93
68	Synthesis of novel 5-substituted indirubins as protein kinases inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14, 6434-6443.	1.4	93
69	Activation of a Plasmodium falciparum cdc2-related Kinase by Heterologous p25 and Cyclin H. Journal of Biological Chemistry, 2000, 275, 8952-8958.	1.6	91
70	Purification of GSK-3 by Affinity Chromatography on Immobilized Axin. Protein Expression and Purification, 2000, 20, 394-404.	0.6	90
71	10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A. Journal of Medicinal Chemistry, 2015, 58, 3131-3143.	2.9	87
72	Cyclin-Dependent Kinase Inhibition by New C-2 Alkynylated Purine Derivatives and Molecular Structure of a CDK2â^'Inhibitor Complex. Journal of Medicinal Chemistry, 2000, 43, 1282-1292.	2.9	86

#	Article	IF	Citations
73	Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene, 2004, 23, 4400-4412.	2.6	86
74	9-Cyano-1-azapaullone (Cazpaullone), a Glycogen Synthase Kinase-3 (GSK-3) Inhibitor Activating Pancreatic Î² Cell Protection and Replication. Journal of Medicinal Chemistry, 2008, 51, 2196-2207.	2.9	85
75	Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues : A novel DYRK1A inhibitor class. European Journal of Medicinal Chemistry, 2012, 49, 379-396.	2.6	84
76	Delayed Treatment with Systemic (S)-Roscovitine Provides Neuroprotection and Inhibits In Vivo CDK5 Activity Increase in Animal Stroke Models. PLoS ONE, 2010, 5, e12117.	1.1	83
77	Inverse In Silico Screening for Identification of Kinase Inhibitor Targets. Chemistry and Biology, 2007, 14, 1207-1214.	6.2	80
78	Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4566-4569.	1.0	79
79	Properties and Potential Applications of Chemical Inhibitors of Cyclin-Dependent Kinases. , 1999, 82, 279-284.		78
80	Targeting cyclin-dependent kinases in anti-neoplastic therapy. Current Opinion in Cell Biology, 2013, 25, 772-779.	2.6	78
81	Protein kinases as drug targets in parasitic protozoa. Trends in Parasitology, 2002, 18, 366-371.	1.5	75
82	3â€˜-Substituted 7-Halogenoindirubins, a New Class of Cell Death Inducing Agents. Journal of Medicinal Chemistry, 2006, 49, 4638-4649.	2.9	75
83	Crystal Structure of Pyridoxal Kinase in Complex with Roscovitine and Derivatives. Journal of Biological Chemistry, 2005, 280, 31220-31229.	1.6	74
84	Modular Asymmetric Synthesis of Aigialomycin D, a Kinase-Inhibitory Scaffold. Angewandte Chemie - International Edition, 2006, 45, 3951-3954.	7.2	74
85	Generation of New Protein Kinase Inhibitors Utilizing Cytochrome P450 Mutant Enzymes for Indigoid Synthesis. Journal of Medicinal Chemistry, 2004, 47, 3236-3241.	2.9	73
86	CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19525-19530.	3.3	73
87	Antimalarial drug discovery: targeting protein kinases. Expert Opinion on Therapeutic Targets, 2007, 11, 279-290.	1.5	72
88	Synthesis and biological activities of aminopyrimidyl-indoles structurally related to meridianins. Bioorganic and Medicinal Chemistry, 2009, 17, 4420-4424.	1.4	72
89	Characterization of maturation-activated histone H1 and ribosomal S6 kinases in sea star oocytes. Biochemistry, 1987, 26, 7960-7968.	1.2	70
90	2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 567-569.	1.0	70

#	Article	IF	Citations
91	Cyclin-dependent kinase inhibitor indirubin-3â€²-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene, 2004, 23, 8206-8215.	2.6	69
92	Antimalarial potential of xestoquinone, a protein kinase inhibitor isolated from a Vanuatu marine sponge Xestospongia sp.. Bioorganic and Medicinal Chemistry, 2006, 14, 4477-4482.	1.4	69
93	Purine-Based Inhibitors of Inositol-1,4,5-trisphosphate-3-kinase. ChemBioChem, 2002, 3, 897-901.	1.3	68
94	6-Br-5methylindirubin-3â€²oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: Exploitation of GSK-3 for treating leishmaniasis. International Journal for Parasitology, 2009, 39, 1289-1303.	1.3	67
95	Pyrazolo[1,5-a]-1,3,5-triazine as a Purine Bioisostere: Access to Potent Cyclin-Dependent Kinase Inhibitor (R)-Roscovitine Analogue. Journal of Medicinal Chemistry, 2009, 52, 655-663.	2.9	67
96	CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes and Cancer, 2010, 1, 369-380.	0.6	67
97	Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases. ACS Medicinal Chemistry Letters, 2013, 4, 22-26.	1.3	65
98	Pyrazolo[3,4-c]pyridazines as Novel and Selective Inhibitors of Cyclin-Dependent Kinases. Journal of Medicinal Chemistry, 2005, 48, 6843-6854.	2.9	63
99	p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene, 2002, 21, 6413-6424.	2.6	62
100	Purification of CK1 by affinity chromatography on immobilised axin. Protein Expression and Purification, 2007, 54, 101-109.	0.6	61
101	Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents. European Journal of Medicinal Chemistry, 2012, 58, 543-556.	2.6	61
102	Starfish oocyte maturation: 1-Methyladenine triggers a drop of cAMP concentration related to the hormone-dependent period. Developmental Biology, 1987, 121, 306-315.	0.9	60
103	An Integrated Computational Approach to the Phenomenon of Potent and Selective Inhibition of Aurora Kinases B and C by a Series of 7-Substituted Indirubins. Journal of Medicinal Chemistry, 2007, 50, 4027-4037.	2.9	60
104	CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle, 2012, 11, 4040-4046.	1.3	60
105	Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. Bioorganic and Medicinal Chemistry, 1999, 7, 1281-1293.	1.4	59
106	Arachidonic acid, 12- and 15-hydroxyeicosatetraenoic acids, eicosapentaenoic acid, and phospholipase A2 induce starfish oocyte maturation. Developmental Biology, 1984, 106, 368-378.	0.9	58
107	Structure-activity relationships and inhibitory effects of various purine derivatives on the in vitro growth of Plasmodium falciparum11Abbreviations: CDK, cyclin-dependent kinase; CDK1, cyclin-dependent kinase 1; and PfPK, Plasmodium falciparum protein kinase.. Biochemical Pharmacology, 2001, 62, 341-348.	2.0	58
108	Intra-M Phase-promoting Factor Phosphorylation of Cyclin B at the Prophase/Metaphase Transition. Journal of Biological Chemistry, 1999, 274, 11977-11986.	1.6	57

#	Article	IF	Citations
109	Cyclin Eâ€“Cdk2 Phosphorylation Promotes Late G1-Phase Degradation of MyoD in Muscle Cells. Experimental Cell Research, 2000, 259, 300-307.	1.2	57
110	Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3419-3423.	1.0	57
111	Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography. Biotechnology Journal, 2007, 2, 68-75.	1.8	57
112	Synthesis, Resolution, and Biological Evaluation of Atropisomeric (aR)- and (aS)-16-Methyllamellarins N: Unique Effects of the Axial Chirality on the Selectivity of Protein Kinases Inhibition. Journal of Medicinal Chemistry, 2013, 56, 7289-7301.	2.9	56
113	TRPC6 channel translocation into phagosomal membrane augments phagosomal function. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6486-95.	3.3	56
114	Novel 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: Synthesis, biological evaluation and molecular modeling studies. European Journal of Medicinal Chemistry, 2008, 43, 1469-1477.	2.6	55
115	Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opinion on Therapeutic Patents, 2010, 20, 377-404.	2.4	55
116	Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E. Cancer Research, 2011, 71, 3377-3386.	0.4	55
117	Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	55
118	Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents. Bioorganic and Medicinal Chemistry, 2008, 16, 4932-4953.	1.4	54
119	Synthesis and kinase inhibitory activity of novel substituted indigoids. Bioorganic and Medicinal Chemistry, 2009, 17, 6257-6263.	1.4	54
120	3,6-Diamino-4-(2-halophenyl)-2-benzoylthieno[2,3-b]pyridine-5-carbonitriles Are Selective Inhibitors of Plasmodium falciparum Glycogen Synthase Kinase-3. Journal of Medicinal Chemistry, 2013, 56, 264-275.	2.9	54
121	Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview. International Journal of Molecular Sciences, 2021, 22, 6047.	1.8	54
122	Chemical inhibitors of cyclin-dependent kinases. , 1995, 1, 351-363.		54
123	Starfish oocyte maturation: Evidence for a cyclic AMP-dependent inhibitory pathway. Developmental Biology, 1989, 133, 58-66.	0.9	51
124	N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine. Molecular Cancer Therapeutics, 2008, 7, 2713-2724.	1.9	51
125	Novel Tetrahydropyrido[1,2-a]isoindolone Derivatives (Valmerins): Potent Cyclin-Dependent Kinase/Glycogen Synthase Kinase 3 Inhibitors with Antiproliferative Activities and Antitumor Effects in Human Tumor Xenografts. Journal of Medicinal Chemistry, 2012, 55, 9589-9606.	2.9	51
126	Acridone Alkaloids from Glycosmis chlorosperma as DYRK1A Inhibitors. Journal of Natural Products, 2014, 77, 1117-1122.	1.5	51

#	Article	IF	Citations
127	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature. Expert Opinion on Therapeutic Patents, 2017, 27, 1183-1199.	2.4	50
128	Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents. Drug Resistance Updates, 2000, 3, 83-88.	6.5	49
129	High-mobility-group proteins P1, I and Y as substrates of the M-phase-specific p34cdc2/cyclincdc13 kinase. FEBS Journal, 1991, 196, 557-567.	0.2	48
130	Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 793-798.	1.0	48
131	Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors. European Journal of Medicinal Chemistry, 2012, 58, 171-183.	2.6	47
132	Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis. Human Molecular Genetics, 2016, 25, 2245-2255.	1.4	46
133	Pyrazolo[3,4- b]quinoxalines. A new class of cyclin-Dependent kinases inhibitors. Bioorganic and Medicinal Chemistry, 2002, 10, 2177-2184.	1.4	45
134	Inhibition of cyclinâ€dependent kinases induces differentiation of supernumerary hair cells and Deiters' cells in the developing organ of Corti. FASEB Journal, 2003, 17, 1-26.	0.2	45
135	Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety. Journal of Natural Products, 2008, 71, 689-692.	1.5	45
136	From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity. Antimicrobial Agents and Chemotherapy, 2016, 60, 2822-2833.	1.4	45
137	Protein phosphorylation and oocyte maturation. Experimental Cell Research, 1986, 163, 477-488.	1.2	44
138	Novel CDK inhibition profiles of structurally varied 1-aza-9-oxafluorenes. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 823-825.	1.0	44
139	Pharmacological Assessment Defines Leishmania donovani Casein Kinase 1 as a Drug Target and Reveals Important Functions in Parasite Viability and Intracellular Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 1501-1515.	1.4	44
140	Coscinosulfate, a CDC25 phosphatase inhibitor from the sponge Coscinoderma mathewsi. Bioorganic and Medicinal Chemistry, 2001, 9, 3049-3054.	1.4	43
141	Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents. European Journal of Medicinal Chemistry, 2011, 46, 5416-5434.	2.6	43
142	Protein phosphorylation and oocyte maturation. Experimental Cell Research, 1986, 163, 489-499.	1.2	42
143	(R)-Roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Experimental Cell Research, 2006, 312, 2394-2400.	1.2	42
144	Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases. European Journal of Medicinal Chemistry, 2013, 59, 283-295.	2.6	41

#	Article	IF	Citations
145	Synthesis and molecular modelling studies of 8-arylpyrido[3â€²,2â€²:4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors. European Journal of Medicinal Chemistry, 2015, 92, 124-134.	2.6	41
146	Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a. Human Molecular Genetics, 2019, 28, 1561-1577.	1.4	41
147	Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part I. Molecules, 2014, 19, 15546-15571.	1.7	41
148	Discovery of the First Potent and Selective Inhibitors of Human dCTP Pyrophosphatase 1. Journal of Medicinal Chemistry, 2016, 59, 1140-1148.	2.9	40
149	Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors. European Journal of Medicinal Chemistry, 2010, 45, 805-810.	2.6	39
150	Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted Pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors. European Journal of Medicinal Chemistry, 2014, 80, 352-363.	2.6	39
151	Differential regulation of histone H1 and ribosomal S6 kinases during sea star oocyte maturation. Biochemistry, 1987, 26, 7968-7974.	1.2	38
152	Epoxide-containing side chains enhance antiproliferative activity of paullones. European Journal of Medicinal Chemistry, 2005, 40, 655-661.	2.6	38
153	Structure-Aided Optimization of Kinase Inhibitors Derived from Alsterpaullone. ChemBioChem, 2005, 6, 541-549.	1.3	38
154	Plasmodium falciparum NIMA-related kinase Pfnek-1: sex specificity and assessment of essentiality for the erythrocytic asexual cycle. Microbiology (United Kingdom), 2011, 157, 2785-2794.	0.7	38
155	Biosynthesis of New Indigoid Inhibitors of Protein Kinases Using Recombinant Cytochrome P450 2A6. Chemistry and Biodiversity, 2005, 2, 51-65.	1.0	37
156	Human cells enter mitosis with damaged DNA after treatment with pharmacological concentrations of genotoxic agents. Biochemical Journal, 2012, 446, 373-381.	1.7	37
157	Indirubin Derivative 6BIO Suppresses Metastasis. Cancer Research, 2013, 73, 6004-6012.	0.4	37
158	Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases. Marine Drugs, 2017, 15, 316.	2.2	37
159	Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography. Biochemical Pharmacology, 2002, 64, 819-825.	2.0	36
160	Synthesis, Biological Evaluation, and Molecular Modeling of Natural and Unnatural Flavonoidal Alkaloids, Inhibitors of Kinases. Journal of Medicinal Chemistry, 2012, 55, 2811-2819.	2.9	36
161	Calmodulin in starfish oocytes. Developmental Biology, 1981, 88, 318-324.	0.9	35
162	Cinnamaldehydes inhibit cyclin dependent kinase 4/cyclin D1. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1819-1822.	1.0	35

#	Article	IF	Citations
163	Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Research and Treatment, 2012, 132, 575-588.	1.1	35
164	Stimulation of protein phosphorylation during fertilization-induced maturation of Urechis caupo oocytes. Developmental Biology, 1982, 94, 62-70.	0.9	34
165	Interaction between the cell-cycle-control proteins p34cdc2 and p9CKShs2. Evidence for two cooperative binding domains in p9CKShs2. FEBS Journal, 1992, 203, 353-360.	0.2	34
166	A western blot assay to measure cyclin dependent kinase activity in cells or in vitro without the use of radioisotopes. FEBS Letters, 2013, 587, 3089-3095.	1.3	34
167	Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray coâ€“crystal structure. European Journal of Medicinal Chemistry, 2016, 118, 170-177.	2.6	34
168	M-phase-specific protein kinase from mitotic sea urchin eggs: Cyclic activation depends on protein synthesis and phosphorylation but does not require DNA or RNA synthesis. Experimental Cell Research, 1989, 183, 361-375.	1.2	33
169	Characterization of two T. gondii CK1 isoforms. Molecular and Biochemical Parasitology, 2005, 141, 15-27.	0.5	33
170	Potent inhibitors of CDK5 derived from roscovitine: Synthesis, biological evaluation and molecular modelling. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 125-131.	1.0	33
171	9- and 11-substituted 4-azapaullones are potent and selective inhibitors of African trypanosoma. European Journal of Medicinal Chemistry, 2014, 83, 274-283.	2.6	33
172	Arachidonic acid metabolism in starfish oocytes. Developmental Biology, 1986, 114, 22-33.	0.9	32
173	Antiinflammatory, analgesic and kinase inhibition activities of some acridine derivatives. Open Chemistry, 2004, 2, 1-15.	1.0	32
174	Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor. European Journal of Medicinal Chemistry, 2017, 125, 696-709.	2.6	32
175	Synthesis and evaluation of the antiproliferative activity of novel thiazoloquinazolinone kinases inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2005, 20, 557-568.	2.5	31
176	Inhibition of NF-ÎºBâ€“Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells. Clinical Cancer Research, 2013, 19, 2393-2405.	3.2	31
177	Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice. Acta Neuropathologica Communications, 2019, 7, 46.	2.4	31
178	Towards the syntheses of Nâ€H and Nâ€alkylated derivatives of meridianins. Journal of Heterocyclic Chemistry, 2007, 44, 793-801.	1.4	30
179	cdc-Like/Dual-Specificity Tyrosine Phosphorylationâ€“Regulated Kinases Inhibitor Leucettine L41 Induces mTOR-Dependent Autophagy: Implication for Alzheimerâ€™s Disease. Molecular Pharmacology, 2014, 85, 441-450.	1.0	30
180	CDK1-Inhibitory Activity of Paullones Depends on Electronic Properties of 9-Substituents. Archiv Der Pharmazie, 2004, 337, 486-492.	2.1	29

#	Article	IF	Citations
181	A One-Pot Synthesis and Biological Activity of Ageladine A and Analogues. Journal of Medicinal Chemistry, 2011, 54, 2492-2503.	2.9	29
182	Library-based Discovery of DYRK1A/CLK1 Inhibitors from Natural Product Extracts. Planta Medica, 2012, 78, 951-956.	0.7	29
183	Dispacamide E and other bioactive bromopyrrole alkaloids from two Indonesian marine sponges of the genus Stylissa. Natural Product Research, 2015, 29, 231-238.	1.0	29
184	Novel Mouse Tauopathy Model for Repetitive Mild Traumatic Brain Injury: Evaluation of Long-Term Effects on Cognition and Biomarker Levels After Therapeutic Inhibition of Tau Phosphorylation. Frontiers in Neurology, 2019, 10, 124.	1.1	29
185	Activation of calmodulin-dependent NAD+ kinase by trypsin. BBA - Proteins and Proteomics, 1982, 702, 143-146.	2.1	28
186	Evaluation of the First Cytostatically Active 1-Aza-9-oxafluorenes as Novel Selective CDK1 Inhibitors with P-Glycoprotein Modulating Properties. Journal of Medicinal Chemistry, 2003, 46, 876-879.	2.9	28
187	Chloromethylhalicyclamine B, a Marine-Derived Protein Kinase CK1Î´/Îµ Inhibitor. Journal of Natural Products, 2016, 79, 2953-2960.	1.5	28
188	In Vitro Activities of Two Antimitotic Compounds, Pancratistatin and 7-Deoxynarciclasine, against Encephalitozoon intestinalis , a Microsporidium Causing Infections in Humans. Antimicrobial Agents and Chemotherapy, 2001, 45, 3409-3415.	1.4	27
189	Synthesis of Paullones with Aminoalkyl Side Chains. Archiv Der Pharmazie, 2002, 335, 311-317.	2.1	27
190	Access to Paullone Analogues by IntramolecularHeck Reaction. Helvetica Chimica Acta, 2007, 90, 753-763.	1.0	27
191	Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3KÎ± inhibitors. European Journal of Medicinal Chemistry, 2012, 57, 225-233.	2.6	27
192	Cyclin-dependent kinase inhibitors closer to market launch?. Expert Opinion on Therapeutic Patents, 2013, 23, 945-963.	2.4	27
193	Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling. FASEB Journal, 2001, 15, 1-22.	0.2	26
194	Polyprenyl-hydroquinones and -furans from three marine sponges inhibit the cell cycle regulating phosphatase CDC25A. Natural Product Research, 2004, 18, 1-9.	1.0	26
195	Development of 5-benzylpaullones and paullone-9-carboxylic acid alkyl esters as selective inhibitors of mitochondrial malate dehydrogenase (mMDH). European Journal of Medicinal Chemistry, 2010, 45, 335-342.	2.6	26
196	Synthesis and biological evaluation of analogs of the marine alkaloids granulatimide and isogranulatimide. European Journal of Medicinal Chemistry, 2012, 54, 626-636.	2.6	26
197	Novel Adociaquinone Derivatives from the Indonesian Sponge Xestospongia sp.. Marine Drugs, 2015, 13, 2617-2628.	2.2	25
198	Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors. Virology, 2011, 415, 56-68.	1.1	24

#	Article	IF	Citations
199	Advances in tetrahydropyrido[1,2- a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors. European Journal of Medicinal Chemistry, 2015, 101, 274-287.	2.6	24
200	A Cdk5 Inhibitor Enhances the Induction of Insulin Secretion by Exendin-4 Both in Vitro and in Vivo. Journal of Physiological Sciences, 2007, 57, 235-239.	0.9	23
201	Concise synthesis and CDK/GSK inhibitory activity of the missing 9-azapaullones. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4940-4944.	1.0	23
202	Use of ATP analogs to inhibit HIV-1 transcription. Virology, 2012, 432, 219-231.	1.1	23
203	Natural Aristolactams and Aporphine Alkaloids as Inhibitors of CDK1/Cyclin B and DYRK1A. Molecules, 2013, 18, 3018-3027.	1.7	23
204	Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis. Neuro-Oncology, 2014, 16, 1484-1498.	0.6	23
205	Induction of Amyloid-Î²42 Production by Fipronil and Other Pyrazole Insecticides. Journal of Alzheimer's Disease, 2018, 62, 1663-1681.	1.2	23
206	7-Bromoindirubin-3â€²-oxime uncovers a serine protease-mediated paradigm of necrotic cell death. Biochemical Pharmacology, 2008, 76, 39-52.	2.0	22
207	Synthesis of new dipyrrolo- and furopyrrolopyrazinones related to tripentones and their biological evaluation as potential kinases (CDKs1â€“5, GSK-3) inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 708-716.	2.6	22
208	Practical Synthesis of Roscovitine and CR8. Organic Process Research and Development, 2009, 13, 641-644.	1.3	22
209	CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases. Drug News and Perspectives, 2006, 19, 325.	1.9	22
210	Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines. European Journal of Medicinal Chemistry, 2013, 62, 728-737.	2.6	21
211	AÎ²-42 lowering agents from the marine-derived fungus Dichotomomyces cejpii. Steroids, 2015, 104, 182-188.	0.8	21
212	Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype. PLoS ONE, 2018, 13, e0196761.	1.1	21
213	Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design. Molecules, 2018, 23, 64.	1.7	21
214	A Small Compound Targeting Prohibitin with Potential Interest for Cognitive Deficit Rescue in Aging mice and Tau Pathology Treatment. Scientific Reports, 2020, 10, 1143.	1.6	21
215	Contrasting effects of fatty acids on oocyte maturation in several starfish species. Prostaglandins, Leukotrienes, and Medicine, 1986, 23, 179-184.	0.8	20
216	Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5/p25. Bioorganic and Medicinal Chemistry, 2011, 19, 359-373.	1.4	20

#	Article	IF	Citations
217	An efficient approach to dispacamide A and its derivatives. Organic and Biomolecular Chemistry, 2012, 10, 978-987.	1.5	20
218	Functional genomics identifyBirc5/Survivinas a candidate gene involved in the chronotoxicity of cyclin-dependent kinase inhibitors. Cell Cycle, 2014, 13, 984-991.	1.3	20
219	Phenanthrene derivatives from Appendicula reflexa as new CDK1/cyclin B inhibitors. Phytochemistry Letters, 2012, 5, 814-818.	0.6	19
220	Synthesis of novel 7-substituted pyrido[2â€²,3â€²:4,5]furo[3,2-d]pyrimidin-4-amines and their N-aryl analogues and evaluation of their inhibitory activity against Ser/Thr kinases. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6784-6788.	1.0	19
221	The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer. Biochemical Pharmacology, 2014, 91, 157-167.	2.0	19
222	Starfish oocyte maturation: from prophase to metaphase. Seminars in Developmental Biology, 1994, 5, 165-171.	1.3	18
223	Rebeccamycin Derivatives as Dual DNA-Damaging Agents and Potent Checkpoint Kinase 1 Inhibitors. Molecular Pharmacology, 2008, 74, 1620-1629.	1.0	18
224	Smallâ€molecule inducers of AÎ²â€42 peptide production share a common mechanism of action. FASEB Journal, 2012, 26, 5115-5123.	0.2	18
225	Aftins Increase Amyloid-Î²42, Lower Amyloid-Î²38, and Do Not Alter Amyloid-Î²40 Extracellular Production in vitro: Toward a Chemical Model of Alzheimer's Disease?. Journal of Alzheimer's Disease, 2013, 35, 107-120.	1.2	18
226	5-Substituted 3-chlorokenpaullone derivatives are potent inhibitors of Trypanosoma brucei bloodstream forms. Bioorganic and Medicinal Chemistry, 2016, 24, 3790-3800.	1.4	18
227	(R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages. Scientific Reports, 2020, 10, 21700.	1.6	18
228	A Pd(0) based cross-coupling approach to the synthesis of 2-amidopurines and their evaluation as CDK inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 130-141.	1.4	17
229	Synthesis and biological evaluation of new penta- and heptacyclic indolo- and quinolinocarbazole ring systems obtained via Pd0 catalysed reductive N-heteroannulation. Organic and Biomolecular Chemistry, 2010, 8, 4625.	1.5	17
230	Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5037-5040.	1.0	17
231	Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4327-4329.	1.0	17
232	The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker. Cellular and Molecular Neurobiology, 1997, 17, 495-507.	1.7	16
233	Indirubins deplete striatal monoamines in the Intact and MPTP-treated mouse brain and block kainate-induced striatal astrogliosis. Neurotoxicology and Teratology, 2010, 32, 212-219.	1.2	16
234	Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis. Frontiers in Cellular and Infection Microbiology, 2017, 7, 243.	1.8	16

#	Article	IF	Citations
235	Genetic and pharmacological inhibition of Cdk1 provides neuroprotection towards ischemic neuronal death. Cell Death Discovery, 2018, 4, 43.	2.0	16
236	Immobilized methylglyoxal-bis(guanylhydrazone) induces starfish oocyte maturation. Developmental Biology, 1983, 100, 308-317.	0.9	15
237	Synthesis of a new series of purine derivatives and their antiâ€cyclinâ€dependent kinase activities. Journal of Heterocyclic Chemistry, 2001, 38, 299-303.	1.4	15
238	An Efficient Method for the Preparation of New Analogs of Leucettamine B under Solvent-Free Microwave Irradiation. Heterocycles, 2009, 78, 1191.	0.4	15
239	Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 1909-1915.	1.4	15
240	[b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors. Molecules, 2019, 24, 4090.	1.7	15
241	Diversity of the intracellular mechanisms underlying the anti-tumor properties of indirubins. International Congress Series, 2007, 1304, 60-74.	0.2	14
242	Catalyst-free synthesis of quinazolin-4-ones from (hetero)aryl-guanidines: application to the synthesis of pyrazolo[4,3-f]quinazolin-9-ones, a new family of DYRK1A inhibitors. Molecular Diversity, 2012, 16, 659-667.	2.1	14
243	Several Human Cyclin-Dependent Kinase Inhibitors, Structurally Related to Roscovitine, As New Anti-Malarial Agents. Molecules, 2014, 19, 15237-15257.	1.7	14
244	New 5-ylidene rhodanine derivatives based on the dispacamide A model. Molecular Diversity, 2014, 18, 375-388.	2.1	14
245	Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors. European Journal of Medicinal Chemistry, 2014, 83, 617-629.	2.6	14
246	Synthesis of Thiazolo[5,4-f]quinazolin-9(8H)-ones as Multi-Target Directed Ligands of Ser/Thr Kinases. Molecules, 2016, 21, 578.	1.7	14
247	Specific Triazine Herbicides Induce Amyloid-Î²42 Production. Journal of Alzheimer's Disease, 2016, 54, 1593-1605.	1.2	14
248	Novel optimization of valmerins (tetrahydropyrido[1,2-a]isoindolones) as potent dual CDK5/GSK3 inhibitors. European Journal of Medicinal Chemistry, 2016, 115, 311-325.	2.6	14
249	Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors. European Journal of Medicinal Chemistry, 2016, 124, 920-934.	2.6	14
250	microRNA machinery is an integral component of drug-induced transcription inhibition in HIV-1 infection. Journal of Rnai and Gene Silencing, 2010, 6, 386-400.	1.2	14
251	Synthesis of New N,N'-Bis(5-arylidene-4-oxo-4,5-dihydrothiazolin-2-yl)piperazine Derivatives Under Microwave Irradiation and Preliminary Biological Evaluation. Scientia Pharmaceutica, 2012, 80, 825-836.	0.7	13
252	Long-Term Fipronil Treatment Induces Hyperactivity in Female Mice. International Journal of Environmental Research and Public Health, 2020, 17, 1579.	1.2	13

#	Article	IF	Citations
253	An Overview of In Vivo and In Vitro Models for Autosomal Dominant Polycystic Kidney Disease: A Journey from 3D-Cysts to Mini-Pigs. International Journal of Molecular Sciences, 2020, 21, 4537.	1.8	13
254	Expression and Activity of Cyclin-Dependent Kinases and Glycogen Synthase Kinase-3 during NT2 Neuronal Differentiation. NeuroSignals, 2004, 13, 134-143.	0.5	12
255	Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3144-3146.	1.0	12
256	Replication-Dependent DNA Damage Response Triggered by Roscovitine Induces an Uncoupling of DNA Replication Proteins. Cell Cycle, 2006, 5, 2153-2159.	1.3	12
257	Structural analogues of roscovitine rescue the intracellular traffic and the function of ER-retained ABCB4 variants in cell models. Scientific Reports, 2019, 9, 6653.	1.6	12
258	8-Dimethylamino-1-methyladenine, a novel potent antagonist of the 1-methyladenine receptor in starfish oocytes. FEBS Journal, 1993, 213, 155-165.	0.2	11
259	Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors. European Journal of Medicinal Chemistry, 2012, 56, 210-216.	2.6	11
260	Synthesis of N,Nâ€²-bis(5-arylidene-4-oxo-3,5-dihydro-4H-imidazol-2-yl)diamines bearing various linkers and biological evaluation as potential inhibitors of kinases. European Journal of Medicinal Chemistry, 2012, 58, 581-590.	2.6	11
261	Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one, a Promising Inhibitor of DYRK1A. Pharmaceuticals, 2019, 12, 185.	1.7	11
262	Trifluoperazine-Sensitive Step during Sea Urchin, Echiuroid and Pelecypod Egg Activation. (trifluoperazine/calmodulin/calcium/maturation/fertilization). Development Growth and Differentiation, 1983, 25, 469-475.	0.6	10
263	CDK1/cyclin B regulation during oocyte maturation in two closely related lugworm species, Arenicola marina and Arenicola defodiens. Development Growth and Differentiation, 2004, 46, 71-82.	0.6	10
264	Photoreactivity of indirubin derivatives. Photochemical and Photobiological Sciences, 2008, 7, 328-336.	1.6	10
265	N -(1 H -Pyrazol-3-yl)quinazolin-4-amines as a novel class of casein kinase 1Î´/Îµ inhibitors: Synthesis, biological evaluation and molecular modeling studies. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2663-2667.	1.0	10
266	Synthesis and evaluation of new potent inhibitors of CK1 and CDK5, two kinases involved in Alzheimerâ€™s disease. Medicinal Chemistry Research, 2013, 22, 3247-3258.	1.1	9
267	Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2kinase. Journal of Zhejiang University Science B, 2005, 6B, 656-663.	0.4	9
268	Structureâ€“Activity Relationship in the Leucettine Family of Kinase Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 1396-1417.	2.9	9
269	Synthesis and Biological Evaluation of Thienopyrrolizines, a New Family of CDK/GSK-3 Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2004, 19, 585-593.	2.5	8
270	A Practical Approach to New (5Z) 2-Alkylthio-5-arylmethylene-1-methyl-1,5-dihydro-4H-imidazol-4-one Derivatives. Molecules, 2011, 16, 7377-7390.	1.7	8

#	Article	IF	Citations
271	A Simple Isomerization of the Purine Scaffold of a Kinase Inhibitor, Roscovitine, Affords a Four- to Seven-Fold Enhancement of Its Affinity for Four CDKs. Could This Be Traced Back to Conjugation-Induced Stiffenings/Loosenings of Rotational Barriers?. ACS Omega, 2017, 2, 3467-3474.	1.6	8
272	Combined Virtual and Experimental Screening for CK1 Inhibitors Identifies a Modulator of p53 and Reveals Important Aspects of in Silico Screening Performance. International Journal of Molecular Sciences, 2017, 18, 2102.	1.8	8
273	A Collection of Bioactive Nitrogen-Containing Molecules from the Marine Sponge Acanthostrongylophora ingens. Marine Drugs, 2019, 17, 472.	2.2	8
274	An expeditious, environment-friendly, and microwave-assisted synthesis of 5-isatinylidenerhodanine derivatives. Chemical Papers, 2011, 65, .	1.0	7
275	Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice. BMC Pharmacology & Toxicology, 2013, 14, 50.	1.0	7
276	Synthesis of Bioactive 2-(Arylamino)thiazolo[5,4-f]-quinazolin-9-ones via the HÃ¼gershoff Reaction or Cu- Catalyzed Intramolecular C-S Bond Formation. Molecules, 2016, 21, 794.	1.7	7
277	Development of Kinase Inhibitors via Metal-Catalyzed Câ€“H Arylation of 8-Alkyl-thiazolo[5,4-f]-quinazolin-9-ones Designed by Fragment-Growing Studies. Molecules, 2018, 23, 2181.	1.7	7
278	Exploring Kinase Inhibition Properties of 9H-pyrimido[5,4-b]- and [4,5-b]indol-4-amine Derivatives. Pharmaceuticals, 2020, 13, 89.	1.7	7
279	Calmodulin in starfish oocytes. Developmental Biology, 1984, 101, 257-262.	0.9	6
280	Identification of potential cellular targets of aloisine A by affinity chromatography. Bioorganic and Medicinal Chemistry, 2009, 17, 5572-5582.	1.4	6
281	A facile consensus ranking approach enhances virtual screening robustness and identifies a cell-active DYRK1Î± inhibitor. Future Medicinal Chemistry, 2018, 10, 2411-2430.	1.1	6
282	Decrease in p3â€Alcβ37 and p3â€Alcβ40, products of Alcadein β generated by γâ€secretase cleavages, in aged monkeys and patients with Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 740-750.	1.8	6
283	Design and Microwave Synthesis of New (5Z) 5-Arylidene-2-thioxo-1,3-thiazolinidin-4-one and (5Z) 2-Amino-5-arylidene-1,3-thiazol-4(5H)-one as New Inhibitors of Protein Kinase DYRK1A. Pharmaceuticals, 2021, 14, 1086.	1.7	6
284	Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study. Journal of Cystic Fibrosis, 2022, 21, 529-536.	0.3	6
285	Microwave Assisted Organic Synthesis (MAOS) of New Dispacamide A Derivatives Bearing a Thiazolinone Platform, Biological Assays on Inhibition of Protein Kinases and Cell Effects. Current Microwave Chemistry, 2014, 1, 33-40.	0.2	5
286	Evaluation of CDK Inhibitor Selectivity. Enzyme Inhibitors Series, 2006, , 103-119.	0.1	5
287	KID, a Kinase Inhibitor Database Project. , 1999, 82, 165-168.		4
288	Characterization of a novel cdk1-related kinase. FEBS Journal, 1999, 264, 55-66.	0.2	4

#	Article	IF	Citations
289	Molecular cloning and characterisation of p15CDK-BP, a novel CDK-binding protein. Biochimica Et Biophysica Acta - Molecular Cell Research, 2002, 1589, 219-231.	1.9	4
290	Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines. Journal of Biomedical Science, 2015, 22, 57.	2.6	4
291	Casein kinase 1Îµ and 1Î± as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8. American Journal of Physiology - Renal Physiology, 2018, 315, F57-F73.	1.3	4
292	Non-Linear Pharmacokinetics of Oral Roscovitine (Seliciclib) in Cystic Fibrosis Patients Chronically Infected with Pseudomonas aeruginosa: A Study on Population Pharmacokinetics with Monte Carlo Simulations. Pharmaceutics, 2020, 12, 1087.	2.0	4
293	Synthesis of 6-Pyridylaminopurines. Heterocycles, 2008, 75, 1735.	0.4	4
294	In vitro Activity of Antimitotic Compounds Against the Microsporidium Encephalitozoon intestinalis. Journal of Eukaryotic Microbiology, 2001, 48, 99s-100s.	0.8	3
295	In Vitro Evaluation of a Novel 2,6,9-Trisubstituted Purine Acting As a Cyclin-Dependent Kinase Inhibitor. Annals of the New York Academy of Sciences, 1999, 886, 180-182.	1.8	2
296	Regulation of M-phase promoting factor (MPF) inNereis virensoocytes during meiotic maturation. Invertebrate Reproduction and Development, 1999, 36, 175-181.	0.3	2
297	Identification of CLK1â€‰Inhibitors by a Fragmentâ€“linking Based Virtual Screening. Molecular Informatics, 2017, 36, 1600123.	1.4	2
298	LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. Oncogenesis, 2021, 10, 40.	2.1	2
299	CDK Inhibitors. , 2002, , 145-167.		2
300	Development, Selectivity, and Application of Paullones, a Family of CDK Inhibitors. Enzyme Inhibitors Series, 2006, , 227-249.	0.1	2
301	Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials. ChemInform, 2003, 34, no.	0.1	0
302	1-Azakenpaullone Is a Selective Inhibitor of Glycogen Synthase Kinase-3Î². ChemInform, 2004, 35, no.	0.1	0
303	The Role of Calmodulin in Oocyte Maturation. , 1985, , 129-145.		0
304	Starfish Oocytes and Sea Urchin Eggs as Models to Study the Intracellular Mechanisms Controlling the Cell Division Cycle. , 1990, , 243-255.		0